In vivo determination of striatal dopamine D2 receptor occupancy in patients treated with olanzapine

Psychiatry Research - Neuroimaging

Volumn 90, Issue 2, 1999, Pages 81-90

  Raedler, Thomas J ^a   Knable, Michael B ^a   Lafargue, Todd ^a   Urbina, Richard A ^a   Egan, Michael F ^a   Pickar, David ^a   Weinberger, Daniel R ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

123I IBZM SPECT; Antipsychotic; Dopamine D2 receptor; Olanzapine; Schizophrenia

Indexed keywords

DOPAMINE 2 RECEPTOR; IODINE 123; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE; OLANZAPINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CORPUS STRIATUM; DOSE RESPONSE; DRUG RECEPTOR BINDING; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; ISOTOPE LABELING; MALE; PRIORITY JOURNAL; RECEPTOR DENSITY; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; BENZAMIDES; BENZODIAZEPINES; CASE-CONTROL STUDIES; CONTRAST MEDIA; CORPUS STRIATUM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; PARKINSON DISEASE, SECONDARY; PIRENZEPINE; PYRROLIDINES; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; SEROTONIN UPTAKE INHIBITORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0033606142     PISSN: 09254927     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0925-4927(99)00010-4     Document Type: Article

References (49)

1. Diagnostic and Statistical Manual of Mental Disorders. 4th edn. 1994;American Psychiatric Association Press, Washington, DC.
2. Baldessarini R.J., Frankenburg F.R. Clozapine. A novel antipsychotic agent. New England Journal of Medicine. 324:1991;746-754.
3. Beasley C.M., Sanger T., Satterlee W., Tollefson G., Tran P., Hamilton S. Olanzapine versus placebo: results of a double-blind, fixed-dosed olanzapine trial. Psychopharmacology. 124:1996;159-167.
4. Beasley C.M., Tollefson G., Tran P., Satterlee W., Sanger T., Hamilton S. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology. 14:1996;111-123.
5. Beasley C.M., Hamilton S.H., Crawford A.M., Dellva M.A., Tollefson G.D., Tran P.V., Blin O., Beuzen J.N. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. European Neuropsychopharmacology. 7:1997;125-137.
6. 123I-IBZM single photon tomography (SPET) study. Psychopharmacology. 117:1995;55-61.
7. Bymaster F.P., Calligaro D.O., Falcone J.F., Marsh R.D., Moore N.A., Tye N.C., Seeman P., Wong D.T. Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology. 14:1996;87-96.
8. 2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Archives of General Psychiatry. 45:1988;71-76.
9. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. >Archives of General Psychiatry. 49:1992;538-544.
10. 11C]raclopride in man. Synapse. 20:1995;200-208.
11. 2 dopamine receptors in the temporal lobe in schizophrenia. A postmortem study. Archives of General Psychiatry. 54:1997;649-658.
12. 125I]epidepride. Synapse. 23:1996;115-123.
13. 2 receptor imaging and neuroleptic response. Journal of Clinical Psychiatry. 57(Suppl. 11):1996;84-88.
14. 2 receptors in basal ganglia and cortex of the human brain. Journal of Pharmacology and Experimental Therapeutics. 257:1991;1253-1263.
15. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Archives of General Psychiatry. 45:1988;789-796.
16. 2 receptor occupancy with low-dose haloperidol treatment: a PET study. American Journal of Psychiatry. 153:1996;948-950.
17. 2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. American Journal of Psychiatry. 155:1998;921-928.
18. Kay S.R., Opler L.A., Fiszbein A. Positive and Negative Syndrome Scale (PANSS) Manual. 1986;Multi-Health Systems, North Tonawanda, NY.
19. Kegeles L.S., Mann J.J. In vivo imaging of neurotransmitter systems using radiolabeled receptor ligands. Neuropsychopharmacology. 17:1997;293-307.
20. 2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics. American Journal of Psychiatry. 153:1996;183-190.
21. Knable M.B., Jones D.W., Coppola R., Hyde T.M., Lee K.S., Gorey J., Weinberger D.R. Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease. Journal of Nuclear Medicine. 36:1995;1216-1225.
22. 123I]-iodobenzamide SPECT study. British Journal of Psychiatry. 171:1997;574-577.
23. 2 receptor occupancy levels. Psychiatry Research: Neuroimaging. 75:1997;91-101.
24. Küfferle B., Brücke T., Topitz-Schratzberger A., Tauscher J., Gossler R., Vesely C., Asenbaum S., Podreka I., Kasper S. Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone. Psychiatry Research: Neuroimaging. 68:1996;23-30.
25. 2 receptor imaging radiopharmaceuticals: synthesis, radiolabeling, and in vitro binding of (R)-(+)- and (S)-(-)-3-iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide. Journal of Medicinal Chemistry. 31:1988;1039-1043.
26. 2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology. 17:1997;162-174.
27. Martin J., Gómez J.C., García-Bernando E., Cuesta M., Alvarez E., Gurpegui M. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. The Spanish group for the study of olanzapine in treatment-refractory schizophrenia. Journal of Clinical Psychiatry. 58:1997;479-483.
28. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biological Psychiatry. 33:1993;227-235.
29. 2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. American Journal of Psychiatry. 152:1995;1444-1449.
30. 2 receptor occupancy in olanzapine-treated patients. Archives of General Psychiatry. 55:1998;283-284.
31. 2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology. 16:1997;1-7.
32. Overall J.E., Gorham D.E. The Brief Psychiatric Rating Scale. Psychological Reports. 10:1962;799-812.
33. 2 dopamine receptor occupancy in clozapine treated patients. American Journal of Psychiatry. 153:1996;1571-1578.
34. 2 dopamine receptor blockade hypothesis of schizophrenia. Lancet. 340:1992;199-202.
35. 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology. 124:1996;148-153.
36. Pilowsky L.S., Mulligan R.S., Acton P.D., Ell P.J., Costa D.C., Kerwin R.W. Limbic selectivity of clozapine. Lancet. 350:1997;490-491.
37. 123I IBZM single photon emission tomography (SPET) study. Psychopharmacology. 130:1997;152-158.
38. 2-dopamine receptor occupancy during treatment with typical and atypical neuroleptics. Biological Psychiatry. 36:1994;627-629.
39. 2 receptors. Life Sciences. 60:1997;207-216.
40. Simpson G.M., Angus J.W.S. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica. 212(Suppl. 44):1970;11-19.
41. 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol. Psychopharmacology. 141:1999;175-181.
42. Tollefson G.D., Sanger T.M. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. American Journal of Psychiatry. 154:1997;466-474.
43. Tollefson G.D., Beasley C.M., Tamura R.N., Tran P.V., Potvin J.H. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. American Journal of Psychiatry. 154:1997;1248-1254.
44. Tollefson G.D., Beasley C.M., Tran P.V., Street J.S., Krueger J.A., Tamura R.N., Graffeo K.A., Thieme M.E. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. American Journal of Psychiatry. 154:1997;457-465.
45. Tran P.V., Dellva M.A., Tollefson G.D., Beasley C.M., Potvin J.H., Kiesler G.M. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. Journal of Clinical Psychiatry. 58:1997;205-211.
46. Tran P.V., Hamilton S.H., Kuntz A.J., Potvin J.H., Andersen S.W., Beasley C., Tollefson G.D. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. Journal of Clinical Psychopharmacology. 17:1997;407-418.
47. Volkow N.D., Fowler J.S., Gatley J., Logan J., Wang G.J., Ding Y.S., Dewey S. PET evaluation of the dopamine system of the human brain. Journal of Nuclear Medicine. 37:1996;1242-1256.
48. Volkow N.D., Gur R.C., Wang G.J., Fowler J.S., Moberg P.J., Ding Y.S., Hitzemann R., Smith G., Logan J. Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. American Journal of Psychiatry. 155:1998;344-349.
49. Wyatt R.J. Practical psychiatric practice: clinical interview forms, rating scales and patient handouts. 1993;American Psychiatric Association Press, Washington, D.C.